Crocins for Health & Longevity - Quick Reference Sheet

Crocins for Health & Longevity

Created on 10/15/2026 – Quick Reference based on Evidence Review created using AI4L + evidence-mcp / Gemini 4 Argon – Audit

Crocins are water-soluble plant pigments in saffron and gardenia fruit used as a dietary supplement to counter cellular stress and inflammation. Oral administration of 15 to 30 milligrams daily relieves nerve pain and tingling, reduces depressive and anxiety symptoms, and modestly lowers blood sugar, with single-group evidence for eye, heart, and lung protection but negligible cholesterol effects. Four-to-twelve-week use is well tolerated with laboratory monitoring. (Full Review)

Protocol

Standard metabolic, ocular, and longevity protocol
15 mg/day orally
Established regimen for diabetic maculopathy, type 2 diabetes glycemic control, and diabetic neuropathy (30 mg/day in psychiatric, COPD, and chemotherapy-neuropathy trials)
Single versus split dosing
15 mg once or twice daily
15 mg/day administered as a single daily capsule; 30 mg/day split into 15 mg twice daily to match crocetin's 6–7 hour half-life
Best time of day
With morning and/or evening meals
Split 30 mg/day protocols administered with morning and evening meals; single 15 mg/day regimens commonly administered with the evening meal for sleep quality and nocturnal recovery
Time to effect
Peripheral Neuropathy Symptom Relief
4–8 weeks
Sensory nerve pain and paresthesia relief at 15–30 mg/day (8–12 week trials)
Depressive and Anxiety Symptom Reduction
2–4 weeks
Depressive and anxiety symptom score reductions at 30 mg/day
Glycemic Control and Insulin Sensitivity
8–12 weeks
HbA1c and fasting blood glucose reductions (alongside retinal thickness and COPD improvements at 8–12 weeks)

Benefits

Contraindications
  • Pregnant and breastfeeding women
  • Individuals with severe renal impairment (serum creatinine >2.0 mg/dL or eGFR <30 mL/min/1.73 m²)
  • Patients with baseline leukopenia (white blood cell count <4,000 cells/μL or absolute neutrophil count <1,500 cells/μL)
  • Individuals with active bleeding disorders or within 2 weeks of major non-cardiac surgery
  • Individuals with known hypersensitivity to Crocus sativus (Iridaceae) or Gardenia jasminoides (Rubiaceae)
Key Interactions
  • Myelosuppressive chemotherapy agents (doxorubicin, cyclophosphamide, paclitaxel)
  • Antidiabetic medications (metformin, glimepiride, insulin)
  • Antihypertensive drugs (amlodipine, losartan, lisinopril)
  • Serotonergic antidepressants (fluoxetine, sertraline, citalopram) (theoretical)
  • Anticoagulants and over-the-counter antiplatelets (warfarin, apixaban, aspirin, ibuprofen) (theoretical)
  • Over-the-counter sedatives and antihistamines (diphenhydramine, doxylamine) (theoretical)
  • Hypoglycemic, hypotensive, and serotonergic supplements (berberine, alpha-lipoic acid, 5-hydroxytryptophan, St. John's wort, Ginkgo biloba) (theoretical)
  • Contrast media and kidney-stressing interventions (iodinated radiocontrast, chronic high-dose nonsteroidal anti-inflammatory drugs)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Leukopenia and white blood cell reduction; serum creatinine elevation; coagulation parameter and amylase reduction; mild gastrointestinal, appetite, and sedative symptoms
  • Speculative: Uterine stimulation and teratogenicity at high doses

Monitoring

Marker Target Why
Fasting Blood Glucose (FBG) 70–99 mg/dL (standard reference range) Efficacy marker: tracks glycemic reduction and checks for additive hypoglycemia.
Hemoglobin A1c (HbA1c) <5.7% (standard reference range) Efficacy marker: evaluates 8–12 week improvement in average glycemic exposure.
High-Sensitivity C-Reactive Protein (hs-CRP) <3.0 mg/L (standard reference range) Efficacy marker: quantifies systemic anti-inflammatory response to crocin.
Serum Creatinine and eGFR Creatinine 0.6–1.2 mg/dL; eGFR >60 mL/min/1.73 m² (standard reference range) Safety check: detects subclinical creatinine elevation (protocols discontinue if creatinine >2.0 mg/dL or eGFR <30 mL/min/1.73 m²).
Complete Blood Count (CBC) with Differential White blood cells 4,500–11,000 cells/μL (standard reference range) Safety check: screens for leukopenia, especially during concurrent chemotherapy.
Central Macular Thickness (via OCT) No established target; reduction from individual baseline Efficacy marker: quantifies resolution of macular thickening in retinal protocols.

Cadence: Baseline laboratory testing (plus seated blood pressure and baseline OCT when targeting macular health); 4 weeks for CBC and blood pressure checks in medicated or chemotherapy-treated individuals; 8 to 12 weeks for metabolic (FBG, HbA1c), inflammatory (hs-CRP), ocular (OCT), and renal (creatinine, eGFR) reassessment, and every 6 months during extended protocols.

Qualitative Assessment

  • Mood and emotional resilience: Depressive and anxious symptom scores at 4 and 8 weeks.
  • Neuropathic sensory comfort: Weekly logs of distal extremity tingling, numbness, or burning pain.
  • Sleep quality and daytime alertness: Daily records of sleep latency and morning restoration.